Bridgewater, NJ (USA), August 8, 2017 – Amneal Pharmaceuticals LLC has launched oseltamivir phosphate capsules, USP in three strengths: 30 mg, 45 mg and 75 mg. The Amneal generic is an AB-rated therapeutic equivalent to Tamiflu®. Each strength is available in 10-count blister dose-packs.
“Flu season is closer than we realize,” says Jim Luce, Amneal Executive Vice President, Sales & Marketing. “Amneal strives to assist healthcare providers and their patients by providing more affordable and greater access to treatment with our generic medication.”
Manufactured in the recently expanded Brookhaven, NY, Amneal facility, oseltamivir capsules began shipping July 11th from the company’s Glasgow, KY distribution center and can be purchased through major wholesalers and distributors.
Annual U.S. sales of Tamiflu® were $444 million according to May 2017 QuintilesIMS market data.
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in its operations in North America, Asia, Australia and Europe, working together to bring high-quality, affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.
All trademarks listed in this release are property of their respective owners.
Jim Luce (sales)
Executive Vice President, Sales & Marketing
Cheryl Lechok (media)
President, Cheryl Lechok Communications